Phase-3 trial of COVAXIN to begin in Lucknow, Gorakhpur from October

Published On 2020-09-27 04:15 GMT   |   Update On 2020-09-27 04:15 GMT

Lucknow: The Uttar Pradesh government on Thursday announced that phase-3 trial of the coronavirus vaccine 'COVAXIN' will start in Lucknow and Gorakhpur from October.

"The phase-3 trial of COVAXIN being developed by Bharat Biotech will start in Lucknow and Gorakhpur from October," said Uttar Pradesh Principal Health Secretary Amit Mohan Prasad here in a press conference.
The Indian Council for Medical Research (ICMR) is collaborating with Bharat Biotech for the development of the COVAXIN.
Meanwhile, Congress leader Deepak Singh on Thursday wrote a letter to Chief Minister Yogi Adityanath and requested to increase testing for Covid-19 in Uttar Pradesh.
According to the Union Health Ministry as of Thursday, there are 61,698 active cases in the state with 3,02,689 recovered people and 5,299 deaths.


Tags:    
Article Source : ANI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News